ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 154 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 7.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,106 | -3.9% | 2,557 | +50.6% | 0.00% | – |
| Q2 2023 | $8,439 | +250.0% | 1,698 | +248.0% | 0.00% | – |
| Q1 2023 | $2,411 | -88.5% | 488 | -85.3% | 0.00% | – |
| Q4 2022 | $20,946 | -61.2% | 3,330 | -32.4% | 0.00% | – |
| Q3 2022 | $54,000 | -14.3% | 4,923 | -10.1% | 0.00% | – |
| Q2 2022 | $63,000 | +80.0% | 5,474 | +41.9% | 0.00% | – |
| Q1 2022 | $35,000 | -16.7% | 3,858 | +35.5% | 0.00% | – |
| Q4 2021 | $42,000 | +200.0% | 2,848 | +420.7% | 0.00% | – |
| Q3 2021 | $14,000 | -94.8% | 547 | -94.7% | 0.00% | -100.0% |
| Q2 2021 | $271,000 | -26.0% | 10,410 | +0.4% | 0.00% | 0.0% |
| Q1 2021 | $366,000 | +5128.6% | 10,368 | +3390.9% | 0.00% | – |
| Q4 2020 | $7,000 | +250.0% | 297 | +494.0% | 0.00% | – |
| Q3 2020 | $2,000 | -33.3% | 50 | -31.5% | 0.00% | – |
| Q2 2020 | $3,000 | +200.0% | 73 | +46.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $16,381,000 | 9.53% |
| Wildcat Capital Management, LLC | 2,128,370 | $19,389,000 | 4.96% |
| TPG GP A, LLC | 18,716,306 | $170,506,000 | 2.11% |
| Pier Capital, LLC | 746,669 | $6,802,000 | 0.87% |
| Coastal Bridge Advisors, LLC | 401,929 | $3,662,000 | 0.84% |
| HARBOR CAPITAL ADVISORS, INC. | 92,755 | $845,000 | 0.40% |
| Lombard Odier Asset Management (Switzerland) SA | 501,219 | $4,566,000 | 0.36% |
| Navalign, LLC | 74,271 | $623,000 | 0.26% |
| PDT Partners, LLC | 241,592 | $2,201,000 | 0.19% |
| GSA CAPITAL PARTNERS LLP | 148,804 | $1,356,000 | 0.18% |